Every schedule here says who ran it before it says a number

Amount

2.4 mg at maintenance, reached through a 16 week escalation

Frequency

Once weekly

Route

Subcutaneous injection

Duration

68 weeks including the escalation

What was measured

Percentage change in body weight from baseline to week 68, and the proportion losing at least 5 percent of body weight, both co-primary. Absolute weight in kilograms, cardiometabolic risk factors and participant reported physical functioning were secondary.

What it cannot tell you

Every participant also received lifestyle counselling, so the schedule was never tested on its own and the drug cannot be separated from the programme around it. The trial excluded people with diabetes, so the numbers do not transfer to them. 68 weeks says nothing about year three, and the trial measured weight rather than any outcome a person cares about underneath it. The escalation exists because the drug is hard to tolerate, and 4.5 percent still stopped for gut side effects with a trial team monitoring them.

Not advice. This is a record of a schedule, not a dose for you.

Amount

5 mg, 10 mg or 15 mg at maintenance, by randomised assignment

Frequency

Once weekly

Route

Subcutaneous injection

Duration

72 weeks in the primary treatment period

What was measured

Percentage change in body weight at week 72 and the proportion reaching a reduction of at least 5 percent, both co-primary. Body composition, waist circumference and cardiometabolic measures were secondary.

What it cannot tell you

Weight was the endpoint. This trial did not measure heart attacks, strokes or deaths, and the cardiovascular indication tirzepatide later received rests on a different trial in a different population. Everyone here was supported by a lifestyle programme and monitored by a trial team, and people with diabetes were excluded. The escalation is a tolerability device rather than a target, and a person who cannot hold the assigned maintenance dose has no number in this table that belongs to them.

Not advice. This is a record of a schedule, not a dose for you.

Amount

1 mg, 4 mg, 8 mg or 12 mg at maintenance, from a starting dose of either 2 mg or 4 mg

Frequency

Once weekly

Route

Subcutaneous injection

Duration

48 weeks in the phase 2 trial. The phase 3 TRIUMPH-1 ran 80 weeks with a further 24 week extension.

What was measured

Percentage change in body weight from baseline to 24 weeks, primary. Percentage change at 48 weeks and the proportions reaching 5, 10 and 15 percent reductions were secondary. Safety, gastrointestinal events and heart rate were assessed.

What it cannot tell you

Retatrutide is not approved anywhere, for anything. Every milligram figure above comes from a 338 person phase 2 whose primary endpoint was 24 weeks, and phase 2 doses are chosen to find the range rather than to be correct. The registry does not publish the phase 3 arm doses, so nobody outside Lilly can say what the trial that reported 28.3 percent actually gave. Heart rate rose with dose. Material sold as retatrutide is not made by the sponsor and nothing verifies its identity or content.

Not advice. This is a record of a schedule, not a dose for you.

Amount

2 mg

Frequency

Once daily

Route

Subcutaneous injection

Duration

26 weeks

What was measured

Percent change from baseline in visceral adipose tissue on computed tomography, primary. Triglycerides, the ratio of total cholesterol to HDL cholesterol, IGF-1 and self assessed body image were secondary, with glucose and insulin as glycaemic measures.

What it cannot tell you

The population was people with HIV whose abdominal fat accumulated on antiretroviral therapy, which is not the same as a person who wants a flatter stomach. The endpoint was a fat measurement on a CT scan, so nothing here was measured about heart attacks, diabetes or how long anyone lived. The trial ran 26 weeks and says nothing about what happens after that, or about what happens when the drug stops. IGF-1 rising 81 percent is a signal that the axis moved, not a benefit in itself.

Not advice. This is a record of a schedule, not a dose for you.

Amount

80 mg

Frequency

Once daily

Route

Rectal enema

Duration

Two weeks

What was measured

Change in the Disease Activity Index across two weeks. Nothing about tendon, ligament, joint or muscle healing was measured, because this was a bowel trial.

What it cannot tell you

The one randomised trial of BPC-157 in humans did not separate from placebo. It tested a rectal enema at 80 mg for ulcerative colitis, which is not the route, the dose, the indication or the duration that anybody buying BPC-157 for a tendon is using. It was never published in full, so what is recorded here is an FDA reviewer's account of a meeting abstract rather than a report anyone can read. No trial has ever dosed BPC-157 subcutaneously for an injury and reported a result: the first one, a 120 person phase 2 in hamstring strain, began recruiting in February 2026 and expects primary completion in February 2027.

Not advice. This is a record of a schedule, not a dose for you.

Amount

2 to 4 mg

Frequency

One or two doses in total

Route

Intra-articular injection into the knee, given by a clinician

Duration

A single course, with follow up by telephone 6 to 12 months later

What was measured

Nothing was measured prospectively. Patients were telephoned 6 to 12 months afterwards and asked, from memory, whether their knee pain had improved. There was no validated pain scale, no imaging, no baseline score and no control group.

What it cannot tell you

A retrospective telephone survey of 17 people from one clinic cannot show that anything worked. With no control group there is nothing to compare the reported improvement against, and no way to separate the peptide from the injection itself, from six to twelve months passing, or from a patient's wish to give their doctor a good answer. Recalled pain is not a measurement. The same clinical group produced the other uncontrolled BPC-157 human reports in the literature, so the small human record for this compound is not independent of itself.

Not advice. This is a record of a schedule, not a dose for you.

Amount

Two patterns recur. A matched one at roughly 250 mcg of each, and a front loaded one at 250 to 500 mcg of BPC-157 daily with 2 to 2.5 mg of TB-500 twice a week.

Frequency

BPC-157 once or twice daily. TB-500 either alongside it daily or twice weekly.

Route

Subcutaneous injection, frequently described as being placed near the injury

Duration

Commonly described as four to eight weeks, sometimes run longer

What was measured

Nothing. No blood test, no imaging, no strength or range of motion measure and no validated pain scale is part of this pattern. What gets reported back is how somebody says their injury felt.

What it cannot tell you

Nobody measured anything. There is no trial of BPC-157 with TB-500 in people, in any combination, at any dose, for any injury, so the amounts above have no source beyond repetition. Neither compound has an established human dose. Material sold as TB-500 has been identified in the lab as a seven amino acid fragment rather than thymosin beta 4, so half of this pattern may not be the molecule it is named after. An injury that was going to heal anyway heals during the four to eight weeks somebody runs this, and self reported recovery collected from people who chose to post is the weakest evidence that exists.

Not advice. This is a record of a schedule, not a dose for you.

Amount

Commonly reported as 100 mcg of each

Frequency

Once at night, frequently described as five nights on and two off

Route

Subcutaneous injection, usually on an empty stomach

Duration

Commonly described in blocks of eight to twelve weeks

What was measured

Some people check IGF-1 before and after. Most check nothing. Sleep quality, recovery and body composition are reported by feel, and body composition is almost never scanned.

What it cannot tell you

Both halves push the same growth hormone axis, so nothing about this pattern can tell you which one did anything, and the pair has never been run as a pair in a trial. Most material sold as CJC-1295 without DAC is mod GRF 1-29, so the name on the vial may not be the molecule inside it. A rise in IGF-1 is a surrogate: it says the axis moved, not that anything you wanted happened to your body. Nobody here measured body composition with a scan, nobody was blinded, and sleep improving in the first weeks of anything new is the oldest confound there is.

Not advice. This is a record of a schedule, not a dose for you.

Amount

Compounded vials drawn to amounts the pens do not offer. Starting points as low as 0.25 mg to 1.5 mg weekly of tirzepatide are described, against the 2.5 mg the label starts at.

Frequency

Once weekly

Route

Subcutaneous injection drawn from a compounded vial rather than a fixed dose pen

Duration

Each step held for four weeks or longer, and frequently held at a low dose indefinitely rather than escalated at all

What was measured

Body weight on a home scale, and how the person feels. Almost nobody running this pattern has any of the endpoints the trials used, and nobody is measuring what dose actually reached them from a drawn vial.

What it cannot tell you

Every efficacy number that makes a person want a GLP-1 came from a trial that escalated to a maintenance dose and held it, so somebody who stops at a fraction of that dose has no number to expect. Nobody has trialled sub-label dosing against the label schedule, so whether a slower ramp reduces nausea across the whole course or only moves it later is unmeasured. Compounded vials are not tested for identity and content the way an approved pen is, and drawing a dose from a vial is a different accuracy problem from clicking a pen. Nobody is monitoring any of this.

Not advice. This is a record of a schedule, not a dose for you.

Amount

The same prescribed weekly total, divided. Splitting is not a reason to take more.

Frequency

Two or three smaller injections a week in place of one weekly, or in place of one every two weeks

Route

Whichever route the prescription specifies, intramuscular or subcutaneous

Duration

Ongoing. This is a schedule rather than a course.

What was measured

Total testosterone, free testosterone, bioavailable testosterone and SHBG, on two draws eighteen months apart. The first was taken before any testosterone was prescribed. The second was taken after starting 100 mg of testosterone cypionate a week. No draw time relative to the last injection was recorded on either, and no oestradiol or haematocrit was captured, which is the gap that matters most here and is stated again in the limits below.

What it cannot tell you

The owner's own numbers now sit on this page, and they do not test the position this page is about. Both draws bracket the start of treatment, so they show that testosterone replacement raised his testosterone, which was never in dispute. They contain no comparison against a single weekly injection, no recorded draw time relative to the last shot, no oestradiol and no haematocrit. Draw timing is the whole argument for splitting, so a level without a timestamp cannot support or refute it. No randomised trial of split against single weekly dosing with symptom endpoints exists either, so the position rests on pharmacokinetic reasoning plus practice guidance, not trial evidence. It says nothing about what the right total dose is. One person's numbers are an anecdote with a lab attached; they are published here because this site asks everyone else to show their evidence, not because they settle anything.

Not advice. This is a record of a schedule, not a dose for you.